Common Skin Cancer, Like Christie Brinkley’s, Can Often Be Cured Without Surgery
March 14, 2024 17:42 ET | SkinCure Oncology LLC
Christie Brinkley was diagnosed with common skin cancer and her doctor “stitched me up to perfection,” but most such cancers can be cured without surgery.
Straits Research Pvt Ltd
Actinic Keratosis Treatment Market Size is projected to reach USD 9.22 billion by 2031, growing at a CAGR of 4.1%: Straits Research
March 14, 2024 10:15 ET | Straits Research Private Limited
New York, United States, March 14, 2024 (GLOBE NEWSWIRE) -- The purpose of treating actinic keratosis, a skin condition induced by prolonged sun exposure, is to prevent these precancerous lesions...
logo (1).png
Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
March 12, 2024 02:30 ET | Vidac Pharma Holding PLC
London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555
March 07, 2024 16:35 ET | SkinCure Oncology LLC
BURR RIDGE, Ill., March 07, 2024 (GLOBE NEWSWIRE) -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy...
immunocore-logo-2018
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 January, 2024) Immunocore Holdings plc...
Vidac Pharma to cond
Vidac Pharma to conduct Phase 2b study for actinic keratosis therapeutic candidate VDA-1102 with CentroDerm
December 19, 2023 01:00 ET | Vidac Pharma Holding PLC
London (UK), December 19, 2023 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company, has completed...
Vidac Pharma va mene
Vidac Pharma va mener une étude de phase 2b du VDA-1102, son candidat médicament pour le traitement de la kératose actinique en collaboration avec CentroDerm
December 19, 2023 01:00 ET | Vidac Pharma Holding PLC
Londres (Royaume-Uni), 19 décembre 2023 – Vidac Pharma Holding Plc (Hambourg et Stuttgart : T9G ; ISIN : GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, a...
Derm-Biome-Pharmaceuticals.png
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study
November 28, 2023 10:00 ET | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that...
immunocore-logo-2018
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major...
SNS-INSIDER-300X300.jpg
Skin Cancer Treatment Market to Surpass USD 18.06 Billion by 2030 Driven by Rising Incidence of Skin Cancer and Globalization of Healthcare | Research by SNS Insider
October 16, 2023 09:05 ET | SNS Insider pvt ltd
Pune, Oct. 16, 2023 (GLOBE NEWSWIRE) -- “The Skin Cancer Treatment Market, as per the SNS Insider report, achieved a value of USD 9.98 Billion and is projected to attain USD 18.06 Billion by 2030,...